Artera vs Freenome

Freenome's SimpleScreen CRC starts with a blood draw from an adult aged 45 or older at average risk, and a positive result goes to colonoscopy. ArteraAI starts from the biopsy slide of a patient already diagnosed with prostate or breast cancer. Primary care screening programs and radiation oncology practices order from separate vendors.

FDA approved P250029 in July 2026 on the PREEMPT CRC trial of more than 48,000 asymptomatic adults. The vendor reports 81.1% sensitivity for colorectal cancer, 13.7% for advanced precancerous lesions and 90.4% specificity for advanced neoplasia. Abbott is to commercialize the test exclusively in the US and handle reimbursement, and the approval release gives no price or CLIA lab.

A radiation oncology practice weighing androgen deprivation for prostate cancer would order Artera. Artera says the analysis uses existing H&E slides with no additional staining and returns results within one to two days of the specimen reaching its CLIA lab.